Morgan Stanley maintains Immunocore Holdings at Equal-Weight, lowers price target to $42 from $43
Morgan Stanley kept its Equal-Weight rating on Immunocore Holdings but reduced its price target to $42 from $43, a 2.3% decrease. This implies a 37.8% upside from the Nov 12 close of $30.48, according to the bank.
How this was made

The 30-second read
Why it matters
For traders, the actionable element is the revised valuation view (PT lowered) while the stance (Equal-Weight) remains unchanged.
Market read
A modest price-target cut can slightly pressure sentiment, but unchanged rating and lack of new fundamentals keep impact limited.
What to watch
The article provides no new fundamental driver (trial data, approvals, guidance), so price action is more likely to be driven by broader biotech sentiment than by this PT change alone.
Background
The piece is an analyst-maintenance update from Morgan Stanley, not a company disclosure.
Ticker impact
Morgan Stanley maintained Immunocore at Equal-Weight and cut its price target to $42 from $43, signaling a modest valuation reset for IMCR.
Likely limited downside bias as traders adjust expectations to the lower target, with muted reaction due to no rating change.
A price-target trim without an upgrade or downgrade typically produces small, short-lived sentiment effects rather than a major repricing.
Market effects
Minimal sector read-through, since this is a single-name valuation adjustment with no new clinical, regulatory, or commercial catalyst mentioned.
None indicated.
None indicated.
Counterpoint
Equal-Weight plus a small target reduction may be interpreted as the analyst still sees fair value, limiting the need for traders to cut exposure aggressively.
Key entities
- companyImmunocore Holdings
Subject of the analyst action: maintained Equal-Weight and lowered price target to $42 from $43.
- analyst_firmMorgan Stanley
Issued the rating maintenance and price-target reduction described in the article.